Læknablaðið - 01.04.2016, Blaðsíða 24

184 LÆKNAblaðið 2016/102
Heimildir
1. American Psychiatric Association. Diagnostic and
Statistical Manual of Mental Disorders, Fifth Edition
(DSM-5(TM)). American Psychiatric Publishing,
Arlington, VA 2013.
2. Geller D, March J. Practice parameter for the assessment
and treatment of children and adolescents with obsessi-
ve-compulsive disorder. J Am Acad Child Adolesc
Psychiatry 2012; 51: 98-113.
3. Ivarsson T, Melin K, Wallin L. Categorical and dimensional
aspects of co-morbidity in obsessive-compulsive disorder
(OCD). Eur Child Adolesc Psychiatry 2008; 17: 20-31.
4. POTS Study Team. Cognitive-behavior therapy, sertraline,
and their combination for children and adolescents
with obsessive-compulsive disorder: the Pediatric OCD
Treatment Study (POTS) randomized controlled trial.
JAMA 2004; 292: 1969-76.
5. Torp NC, Dahl K, Skarphedinsson G, Thomsen P,
Valderhaug R, Weidle B, et al. Effectiveness of cognitive
behavior treatment for pediatric obsessive-compulsive
disorder: Acute outcomes from The Nordic Long-term
OCD Treatment Study (NordLOTS). Behav Res Ther 2015;
64: 15-23.
6. Bloch MH, Landeros-Weisenberger A, Rosario MC,
Pittenger C, Leckman JF. Meta-analysis of the symptom
structure of obsessive-compulsive disorder. Am J
Psychiatry 2008; 165: 1532-42.
7. Piacentini J, Bergman RL, Chang S, Langley A, Peris T,
Wood JJ, et al. Controlled comparison of family cognitive
behavioral therapy and psychoeducation/relaxation train-
ing for child obsessive-compulsive disorder. J Am Acad
Child Adolesc Psychiatry 2011; 50: 1149-61.
8. Stewart SE, Geller DA, Jenike M, Pauls D, Shaw D,
Mullin B, et al. Long-term outcome of pediatric obsessi-
ve-compulsive disorder: a meta-analysis and qualitative
review of the literature. Acta Psychiatr Scand 2004; 110:
4-13.
9. Micali N, Heyman I, Perez M, Hilton K, Nakatani E,
Turner C, et al. Long-term outcomes of obsessive-
-compulsive disorder: follow-up of 142 children and
adolescents. Br J Psychiatry 2010; 197: 128-34.
10. Jenike MA, Rauch SL. Managing the patient with treat-
ment-resistant obsessive compulsive disorder: current
strategies. J Clin Psychiatry 1994; 55 Suppl:11-7.
11. Skarphedinsson G, Hanssen-Bauer K, Kornor H,
Heiervang ER, Landro NI, Axelsdottir B, et al. Standard
individual cognitive behaviour therapy for paediatric
obsessive-compulsive disorder: A systematic review of
effect estimates across comparisons. Nord J Psychiatr
2015; 69: 81-92.
12. Ivarsson T, Skarphedinsson G, Kornor H, Axelsdottir B,
Biedilae S, Heyman I, et al. The place of and evidence
for serotonin reuptake inhibitors (SRIs) for obsessive
compulsive disorder (OCD) in children and adolescents:
Views based on a systematic review and meta-analysis.
Psychiatry Res 2015; 227: 93-103.
13. Bloch MH, Storch EA. Assessment and Management of
Treatment-Refractory Obsessive-Compulsive Disorder in
Children. J Am Acad Child Adolesc Psychiatry 2015; 54:
251-62.
14. Sánchez-Meca J, Rosa-Alcázar AI, Iniesta-Sepúlveda
M, Rosa-Alcázar Á. Differential efficacy of cognitive-
-behavioral therapy and pharmacological treatments for
pediatric obsessive–compulsive disorder: A meta-analys-
is. J Anxiety Disord 2014; 28: 31-44.
15. Pittenger C, Bloch MH. Pharmacological treatment of
obsessive-compulsive disorder. Psychiatr Clin North Am
2014; 37: 375-91.
16. Freeman J, Garcia A, Frank H, Benito K, Conelea C,
Walther M, et al. Evidence base update for psychosocial
treatments for pediatric obsessive-compulsive disorder. J
Clin Child Adolesc Psychol 2014; 43: 7-26.
17. Grados MA, Specht MW, Sung HM, Fortune D. Glutamate
drugs and pharmacogenetics of OCD: a pathway-based
exploratory approach. Exp Opin Drug Discov 2013; 8:
1515-27.
18. Dold M, Aigner M, Lanzenberger R, Kasper S.
Antipsychotic augmentation of serotonin reuptake inhi-
bitors in treatment-resistant obsessive-compulsive dis-
order: a meta-analysis of double-blind, randomized,
placebo-controlled trials. Int J Neuropsychopharmacol
2013; 16: 557-74.
19. National Institute for Heath and Clinical Excellence.
Obsessive compulsive disorder (OCD) and body
dysmorphic disorder (BDD) London: National Institute
for Health and Clinical Excellence; 2005. guidance.nice.
org.uk/CG31 - janúar 2016.
20. Peris TS, Compton S, Piacentini J. Trajectories of change in
cognitive behavior therapy for pediatric anxiety. AACAP
59th Annual Meeting; October 23, 2012; San Francisco
2012.
21. Bolton D, Perrin S. Evaluation of exposure with response-
-prevention for obsessive compulsive disorder in child-
hood and adolescence. J Behav Ther Exp Psychiatry 2008;
39: 11-22.
22. March J, Frances A, Carpenter D, Kahn DA. Treatment
of obsessive-compulsive disorder. The Expert Consensus
Panel for obsessive-compulsive disorder. J Clin Psychiatry
1997; 58 Suppl 4:2-72.
23. March JS, Mulle K. OCD in Children and Adolescents: A
cognitive-behavioral treatment manual. Guilford Press,
New York 1998.
24. Foa EB. Cognitive behavioral therapy of obsessive-
-compulsive disorder. Dialogues Clin Neurosci 2010; 12:
199-207.
25. Barrett P, Healy-Farrell L, March JS. Cognitive-behavioral
family treatment of childhood obsessive-compulsive
disorder: a controlled trial. J Am Acad Child Adolesc
Psychiatry 2004; 43: 46-62.
26. Bolton D, Williams T, Perrin S, Atkinson L, Gallop C,
Waite P, et al. Randomized controlled trial of full and brief
cognitive-behaviour therapy and wait-list for paediatric
obsessive-compulsive disorder. J Child Psychol Psychiatr
2011; 52: 1269-78.
27. Storch EA, Caporino NE, Morgan JR, Lewin AB, Rojas A,
Brauer L, et al. Preliminary investigation of web-camera
delivered cognitive-behavioral therapy for youth with
obsessive-compulsive disorder. Psychiatry Res 2011; 189:
407-12.
28. Williams TI, Salkovskis PM, Forrester L, Turner S, White
H, Allsopp MA. A randomised controlled trial of cognitive
behavioural treatment for obsessive compulsive disorder
in children and adolescents. Eur Child Adolesc Psychiatry
2010; 19: 449-56.
29. Lewin AB, Park JM, Jones AM, Crawford EA, De Nadai
AS, Menzel J, et al. Family-based exposure and response
prevention therapy for preschool-aged children with
obsessive-compulsive disorder: A pilot randomized
controlled trial. Behav Res Ther 2014; 56: 30-8.
30. Freeman JB, Garcia AM, Coyne L, Ale C, Przeworski
A, Himle M, et al. Early childhood OCD: preliminary
findings from a family-based cognitive-behavioral app-
roach. J Am Acad Child Adolesc Psychiatry 2008; 47: 593-
602.
31. Freeman J, Sapyta J, Garcia A, Compton S, Khanna
M, Flessner C, et al. Family-based treatment of early
childhood obsessive-compulsive disorder: the Pediatric
Obsessive-Compulsive Disorder Treatment Study for
Young Children (POTS Jr)--a randomized clinical trial.
JAMA Psychiatry 2014; 71: 689-98.
32. de Haan E, Hoogduin KA, Buitelaar JK, Keijsers GP.
Behavior therapy versus clomipramine for the treatment
of obsessive-compulsive disorder in children and ado-
lescents. J Am Acad Child Adolesc Psychiatry 1998; 37:
1022-9.
33. Asbahr FR, Castillo AR, Ito LM, Latorre MRDdO, Moreira
MN, Lotufo-Neto F. Group cognitive-behavioral therapy
versus sertraline for the treatment of children and ado-
lescents with obsessive-compulsive disorder. J Am Acad
Child Adolesc Psychiatry 2005; 44: 1128-36.
34. Scahill L, Riddle MA, McSwiggin-Hardin M, Ort SI, King
RA, Goodman WK, et al. Children‘s Yale-Brown Obsessive
Compulsive Scale: reliability and validity. J Am Acad
Child Adolesc Psychiatry 1997; 36: 844-52.
35. Cohen J. Statistical power analysis for the behavioral sci-
ences. rev. ed. Lawrence Erlbaum Associates. Hillsdale, NJ
1977.
36. Franklin ME, Dingfelder HE, Coogan CG, Garcia AM,
Sapyta JJ, Freeman JL. Cognitive behavioral therapy for
pediatric obsessive-compulsive disorder: development
of expert-level competence and implications for dissem-
ination. J Anxiety Disord 2013; 27: 745-53.
37. Sjúkratryggingar Íslands. Sálfræðiþjónusta 2016 sjukra.is/
heilbrigdisthjonusta/salfraedithjonusta-vid-born/ - janúar
2016.
38. Ginsburg GS, Kingery JN, Drake KL, Grados MA.
Predictors of treatment response in pediatric obsessi-
ve-compulsive disorder. J Am Acad Child Adolesc
Psychiatry 2008; 47: 868-78.
39. Garcia AM, Sapyta JJ, Moore PS, Freeman JB, Franklin ME,
March JS, et al. Predictors and moderators of treatment
outcome in the Pediatric Obsessive Compulsive Treatment
Study (POTS I). J Am Acad Child Adolesc Psychiatry 2010;
49: 1024-33; quiz 86.
40. Torp NC, Dahl K, Skarphedinsson G, Thomsen PH,
Valderhaug R, Weidle B, et al. Predictors associated with
improved cognitive-behavioral therapy outcome in pedi-
atric obsessive-compulsive disorder. J Am Acad Child
Adolesc Psychiatry 2015; 54: 200-7.
41. Storch EA, Merlo LJ, Larson MJ, Geffken GR, Lehmkuhl
HD, Jacob ML, et al. Impact of comorbidity on cogn-
itive-behavioral therapy response in pediatric obsessi-
ve-compulsive disorder. J Am Acad Child Adolesc
Psychiatry 2008; 47: 583-92.
42. Merlo LJ, Lehmkuhl HD, Geffken GR, Storch EA.
Decreased family accommodation associated with
improved therapy outcome in pediatric obsessive-
-compulsive disorder. J Consult Clin Psychol 2009; 77:
355-60.
43. Barrett P, Farrell L, Dadds M, Boulter N. Cognitive-
behavioral family treatment of childhood obsessive-
-compulsive disorder: long-term follow-up and predictors
of outcome. J Am Acad Child Adolesc Psychiatry 2005; 44:
1005-14.
44. Himle JA, Van Etten M, Fischer DJ. Group Cognitive
Behavioral Therapy for Obsessive-Compulsive Disorder:
A Review. Brief Treatment and Crisis Intervention 2003; 3:
217-29.
45. Hudson JL, Rapee RM, Lyneham HJ, McLellan LF,
Wuthrich VM, Schniering CA. Comparing outcomes for
children with different anxiety disorders following cogn-
itive behavioural therapy. Behav Res Ther 2015; 72: 30-7.
46. Tolin DF, Diefenbach GJ, Gilliam CM. Stepped care versus
standard cognitive-behavioral therapy for obsessive-
-compulsive disorder: A preliminary study of efficacy and
costs. Depress Anxiety 2011; 28: 314-23.
47. Lenhard F, Vigerland S, Andersson E, Ruck C, Mataix-Cols
D, Thulin U, et al. Internet-delivered cognitive behavior
therapy for adolescents with obsessive-compulsive dis-
order: an open trial. PLoS ONE 2014; 9: e100773.
48. Turner CM, Mataix-Cols D, Lovell K, Krebs G, Lang K,
Byford S, et al. Telephone Cognitive-Behavioral Therapy
for Adolescents With Obsessive-Compulsive Disorder: A
Randomized Controlled Non-inferiority Trial. J Am Acad
Child Adolesc Psychiatry 2014; 53: 1298-307.e2.
49. March JS, Biederman J, Wolkow R, Safferman A,
Mardekian J, Cook EH, et al. Sertraline in children
and adolescents with obsessive-compulsive disorder: a
multicenter randomized controlled trial. JAMA 1998; 280:
1752-6.
50. Riddle MA, Reeve EA, Yaryura-Tobias JA, Yang HM,
Claghorn JL, Gaffney G, et al. Fluvoxamine for children
and adolescents with obsessive-compulsive disorder:
a randomized, controlled, multicenter trial. J Am Acad
Child Adolesc Psychiatry 2001; 40: 222-9.
51. Riddle MA, Scahill L, King RA, Hardin MT, Anderson
GM, Ort SI, et al. Double-blind, crossover trial of flu-
oxetine and placebo in children and adolescents with
obsessive-compulsive disorder. J Am Acad Child Adolesc
Psychiatry 1992; 31: 1062-9.
Y F I R L I T
Læknablaðið birtir í blaðinu heimildalista við yfirlitsgreinar með allt að 60 heimildum,
– lengri listi er birtur við greinina á heimasíðu blaðsins.
Samstarf heilbrigðisstarfsfólks og lyfja fyrirtækja
hefur haft jákvæð áhrif á þróun meðferða og lyfja.
Þessir aðilar taka iðulega höndum saman við
rannsóknir og fræðslu, til hagsbóta fyrir sjúklinga.

Með innleiðingu siðareglna hafa lyfjafyrirtækin og
heilbrigðisstarfsfólk unnið að því að efla þær reglur
sem samstarf þeirra byggist á. Almenningur á að
geta treyst því að slíkt samstarf hafi ekki áhrif á
klínískar ákvarðanir og að heilbrigðisstarfsfólk
ráðleggi, veiti eða kaupi viðeigandi meðferð og
þjónustu sem byggist eingöngu á klínískum
niðurstöðum og reynslu.

Framkvæmdastjórn ESB hefur gefið út reglur um
eflingu góðra stjórnunarhátta í lyfja iðnaðinum
sem allir hagsmunaaðilar samþykktu árið 2013.
Þessar reglur gera ráð fyrir að upplýsingar um
tilteknar greiðslur verði gerðar opinberar.
EFPIA, Frumtök og öll okkar aðildarfyrirtæki
styðja þessar reglur um birtingu upplýsinga.
Reglurnar kveða á um að öll aðildarfyrirtæki birti
upplýsingar um greiðslur til heilbrigðisstarfsfólks
og -stofnana frá árinu 2016. Þá verða birtar
upplýsingar byggðar á samskiptum ársins 2015 og
þaðan í frá árlega. Þær greiðslur sem reglurnar ná
til eru t.d. styrkir til heilbrigðisstofnana, ráð-
gjafagreiðslur fyrir fyrirlestra, ferða- og dvalar-
kostnaður og skráningargjöld á ráðstefnur. Þessar
upplýsingar verða birtar á heimasíðu Frumtaka,
www.frumtok.is

Markmiðið er að efla samstarf lyfjafyrirtækja og
heilbrigðisstarfsfólks með því að gera það
gegnsærra fyrir sjúklinga og aðra þá sem hagsmuna
eiga að gæta. Við hlökkum til að vinna áfram að því
að auka gæði meðferða, rannsókna og almennrar
umönnunar sjúklinga.
Birting fjárhagsupplýsinga
Við minnum á að fyrir lok júní næstkomandi munu lyfjafyrirtækin í fyrsta skipti birta upplýsingar
um tilteknar greiðslur vegna samstarfs við heilbrigðisstarfsfólk og heilbrigðisstofnanir á árinu
2015. En hvers vegna?
Frekari upplýsingar og kynningarefni:
transparency.efpia.eu | pharmadisclosure.eu
@Pharma2015_16
Frumtök – samtök framleiðenda frumlyfja
Húsi atvinnulífsins, Borgartúni 35, 105
Reykjavík | Sími 588 8955
www.frumtok.is | frumtok@frumtok.is